Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
March 14, 2024 10:31 AM 3 min read

Check Out What Whales Are Doing With VKTX

by Benzinga Insights Benzinga Staff Writer
Follow
VKTX Logo
VKTXViking Therapeutics Inc
$30.661.40%
Overview

Investors with a lot of money to spend have taken a bearish stance on Viking Therapeutics (NASDAQ:VKTX).

And retail traders should know.

We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VKTX, it often means somebody knows something is about to happen.

Today, Benzinga's options scanner spotted 11 options trades for Viking Therapeutics.

This isn't normal.

The overall sentiment of these big-money traders is split between 45% bullish and 54%, bearish.

Out of all of the options we uncovered, there was 1 put, for a total amount of $58,200, and 10, calls, for a total amount of $402,660.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $12.0 and $90.0 for Viking Therapeutics, spanning the last three months.

Volume & Open Interest Trends

In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 348.2 with a total volume of 608.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Viking Therapeutics's big money trades within a strike price range of $12.0 to $90.0 over the last 30 days.

Viking Therapeutics 30-Day Option Volume & Interest Snapshot

Significant Options Trades Detected:

About Viking Therapeutics

Current Position of Viking Therapeutics

  • Currently trading with a volume of 1,142,080, the VKTX's price is down by -2.03%, now at $70.5.
  • RSI readings suggest the stock is currently may be overbought.
  • Anticipated earnings release is in 41 days.

Professional Analyst Ratings for Viking Therapeutics

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $90.2.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Viking Therapeutics, Benzinga Pro gives you real-time options trades alerts.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
OptionsMarketsBZI-UOA
Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
VKTX CALL SWEEP BULLISH 04/19/24 $90.00 $88.5K 794 204
VKTX PUT TRADE BEARISH 04/19/24 $65.00 $58.2K 527 72
VKTX CALL SWEEP BEARISH 08/16/24 $70.00 $45.5K 103 25
VKTX CALL TRADE NEUTRAL 01/16/26 $20.00 $41.5K 204 8
VKTX CALL TRADE BULLISH 04/19/24 $80.00 $41.5K 689 127

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

  • An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $90.
  • An analyst from Truist Securities persists with their Buy rating on Viking Therapeutics, maintaining a target price of $120.
  • Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Viking Therapeutics, targeting a price of $116.
  • An analyst from Stifel persists with their Buy rating on Viking Therapeutics, maintaining a target price of $35.
  • An analyst from HC Wainwright & Co. has decided to maintain their Buy rating on Viking Therapeutics, which currently sits at a price target of $90.
VKTX Logo
VKTXViking Therapeutics Inc
$30.661.40%
Overview
Comments
Loading...